Nickan Research Institute Journal of Parathyroid Disease 2345-6558 6 2 2018 04 01 Anti-receptor activator nuclear factor κ-B ligand (anti-RANKL) as an antiresorptive agent for renal failure osteoporotic patient 33 33 10.15171/jpd.2018.12 EN Mansoor Karimifar Mozhgan Karimifar Journal Article 10.15171/jpd.2018.12 Implication for health policy/practice/research/medical education Treatment for renal failure, especially those who undergo dialysis, is very difficult and challenging. Bisphosphonates have been administered for the treatment of osteoporosis for many years, but they are administered with caution in those who have renal failure. With the introduction of Prolia as an anti-osteoporosis drug, the hope was created to treat patients with kidney failure.